多发性骨髓瘤中的外周血干细胞动员：生长因子还是化疗？
Peripheral blood stem cell mobilization in multiple myeloma: Growth factors or chemotherapy?
作者信息
Wallis Whitney D, Qazilbash Muzaffar H
机构信息
the University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States.
出版信息
World J Transplant. 2017 Oct 24;7(5):250-259. doi: 10.5500/wjt.v7.i5.250.
Abstract
High-dose therapy followed by autologous hematopoietic stem cell (HSC) transplant is considered standard of care for eligible patients with multiple myeloma. The optimal collection strategy should be effective in procuring sufficient HSC while maintaining a low toxicity profile. Currently available mobilization strategies include growth factors alone, growth factors in combination with chemotherapy, or growth factors in combination with chemokine receptor antagonists; however, the optimal strategy has yet to be elucidated. Herein, we review the risks and benefits of each approach.
摘要
大剂量治疗后进行自体造血干细胞（HSC）移植被认为是适合的多发性骨髓瘤患者的标准治疗方法。最佳采集策略应能有效地获取足够的造血干细胞，同时保持低毒性。目前可用的动员策略包括单独使用生长因子、生长因子与化疗联合使用，或生长因子与趋化因子受体拮抗剂联合使用；然而，最佳策略尚未阐明。在此，我们综述了每种方法的风险和益处。
相似文献
1
Peripheral blood stem cell mobilization in multiple myeloma: Growth factors or chemotherapy?
World J Transplant. 2017 Oct 24;7(5):250-259. doi: 10.5500/wjt.v7.i5.250.
2
[Analysis of Success Rate and Influencing Factors for Collecting Peripheral Blood Hematopoietic Stem Cells by Combination of CTX or E-CHOP Chemotherapy with Mobilization of G-CSF in Patients with Multiple Myeloma].
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2018 Jun;26(3):812-816. doi: 10.7534/j.issn.1009-2137.2018.03.030.
3
Hematopoietic progenitor cell mobilization for autologous transplantation - a literature review.
Rev Bras Hematol Hemoter. 2016 Jan-Feb;38(1):28-36. doi: 10.1016/j.bjhh.2015.07.011. Epub 2015 Aug 19.
4
Management of poor peripheral blood stem cell mobilization: incidence, predictive factors, alternative strategies and outcome. A retrospective analysis on 2177 patients from three major Italian institutions.
Transfus Apher Sci. 2009 Aug;41(1):33-7. doi: 10.1016/j.transci.2009.05.011. Epub 2009 Jun 18.
5
Stem cell mobilization in patients with dialysis-dependent multiple myeloma: Report of the Polish Myeloma Study Group.
J Clin Apher. 2018 Jun;33(3):249-258. doi: 10.1002/jca.21584. Epub 2017 Sep 18.
6
Filgrastim-alone versus pegylated filgrastim-alone for autologous peripheral blood stem cells mobilization in newly diagnosed multiple myeloma patients.
Wien Klin Wochenschr. 2017 Aug;129(15-16):545-551. doi: 10.1007/s00508-017-1205-z. Epub 2017 Apr 24.
7
Pegylated Filgrastim Versus Filgrastim for Stem Cell Mobilization in Multiple Myeloma After Novel Agent Induction.
Clin Lymphoma Myeloma Leuk. 2018 Mar;18(3):174-179. doi: 10.1016/j.clml.2017.12.010. Epub 2018 Jan 5.
8
Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of patients with multiple myeloma.
J Hematother. 1996 Aug;5(4):339-49. doi: 10.1089/scd.1.1996.5.339.
9
Current status of art mobilization in Myeloma.
Transfus Apher Sci. 2017 Dec;56(6):850-853. doi: 10.1016/j.transci.2017.11.028. Epub 2017 Nov 21.
10
Peripheral blood stem cell mobilization tactics.
Ann Pharmacother. 2010 Jan;44(1):107-16. doi: 10.1345/aph.1M289. Epub 2009 Dec 8.
引用本文的文献
1
A German-Wide Systematic Study on Mobilization and Collection of Hematopoietic Stem Cells in Poor Mobilizer Patients with Multiple Myeloma prior to Autologous Stem Cell Transplantation.
Transfus Med Hemother. 2023 Oct 16;50(6):475-490. doi: 10.1159/000531935. eCollection 2023 Dec.
2
Cryopreservation and storage patterns of hematopoietic progenitor stem cells for multiple myeloma.
Transfus Apher Sci. 2023 Oct;62(5):103731. doi: 10.1016/j.transci.2023.103731. Epub 2023 May 20.
3
Stem cell mobilization in multiple myeloma: challenges, strategies, and current developments.
Ann Hematol. 2023 May;102(5):995-1009. doi: 10.1007/s00277-023-05170-0. Epub 2023 Mar 22.
4
A Case with Hepatic Involvement Mimicking Metastatic Disease in Multiple Myeloma.
Case Rep Hematol. 2020 Jul 17;2020:5738319. doi: 10.1155/2020/5738319. eCollection 2020.
5
Poor Mobilisation After Daratumumab Based Combination Chemotherapy in Patients of Newly Diagnosed Multiple Myeloma.
Indian J Hematol Blood Transfus. 2019 Jul;35(3):584-586. doi: 10.1007/s12288-019-01135-4. Epub 2019 May 10.
本文引用的文献
1
Modified CVAD and modified CBAD compared to high-dose cyclophosphamide for peripheral blood stem cell mobilization in patients with multiple myeloma.
Eur J Haematol. 2017 Apr;98(4):388-392. doi: 10.1111/ejh.12843. Epub 2017 Jan 30.
2
Lenalidomide consolidation treatment in patients with multiple myeloma suppresses myelopoieses but spares erythropoiesis.
Int J Cancer. 2016 Nov 15;139(10):2343-52. doi: 10.1002/ijc.30257. Epub 2016 Aug 13.
3
Autologous Stem Cell Mobilization in the Age of Plerixafor.
Clin Lymphoma Myeloma Leuk. 2016 Jul;16(7):411-6. doi: 10.1016/j.clml.2016.04.007. Epub 2016 May 5.
4
Bendamustine, etoposide and dexamethasone to mobilize peripheral blood hematopoietic stem cells for autologous transplantation in patients with multiple myeloma.
Bone Marrow Transplant. 2016 Oct;51(10):1330-1336. doi: 10.1038/bmt.2016.123. Epub 2016 May 23.
5
The High Effect of Chemomobilization with High-Dose Etopside + Granulocyte-Colony Stimulating Factor in Autologous Hematopoietic Peripheral Blood Stem Cell Transplantation: A Single Center Experience.
Hematol Rep. 2016 Mar 18;8(1):6319. doi: 10.4081/hr.2016.6319. eCollection 2016 Mar 17.
6
Prognostic factors for re-mobilization using plerixafor and granulocyte colony-stimulating factor (G-CSF) in patients with malignant lymphoma or multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy: the Korean multicenter retrospective study.
Ann Hematol. 2016 Mar;95(4):603-11. doi: 10.1007/s00277-016-2589-y. Epub 2016 Jan 11.
7
Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
Lancet Oncol. 2015 Dec;16(16):1617-29. doi: 10.1016/S1470-2045(15)00389-7. Epub 2015 Nov 17.
8
Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation.
Bone Marrow Transplant. 2015 Dec;50(12):1513-8. doi: 10.1038/bmt.2015.190. Epub 2015 Aug 24.
9
Efficacy of biosimilar granulocyte colony-stimulating factor versus originator granulocyte colony-stimulating factor in peripheral blood stem cell mobilization in de novo multiple myeloma patients.
Cytotherapy. 2015 Oct;17(10):1485-93. doi: 10.1016/j.jcyt.2015.05.010. Epub 2015 Jul 15.
10
Tbo-Filgrastim versus Filgrastim during Mobilization and Neutrophil Engraftment for Autologous Stem Cell Transplantation.
Biol Blood Marrow Transplant. 2015 Nov;21(11):1921-5. doi: 10.1016/j.bbmt.2015.05.024. Epub 2015 May 30.
Zotero 插件